Pfizer (PFE) Net Income towards Common Stockholders (2009 - 2026)

Pfizer (PFE) has reported Net Income towards Common Stockholders for 18 consecutive years, with -$238.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 108.13% year-over-year to -$238.0 million in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 67.84% decrease from a year earlier, with the FY2025 full-year figure at $7.8 billion, down 3.11% from the prior year.
• Net Income towards Common Stockholders was -$238.0 million for Q2 2026 at Pfizer, down from $2.7 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $9.9 billion in Q3 2022 and troughed at -$3.4 billion in Q4 2023.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 6000.0% in 2025 and sank 108.13% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at $9.9 billion in 2022, then sank by 133.9% to -$3.4 billion in 2023, then surged by 327.14% to $7.6 billion in 2024, then plunged by 121.49% to -$1.6 billion in 2025, then soared by 85.49% to -$238.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$238.0 million (Q2 2026), $2.7 billion (Q1 2026), and -$1.6 billion (Q4 2025), per Business Quant data.